Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Hemogenyx Pharmaceuticals Plc. (OP:HOPHF)

0.0031 UNCHANGED
Last Price Updated: 12:21 PM EDT, Aug 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hemogenyx Pharmaceuticals Plc.

< Previous 1 2 3 Next >
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director’s Dealing
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Final Results
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Opening of First Clinical Site
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces First Patient Safety
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
Via ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Final Results
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Via ACCESSWIRE
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be... 
Via TheNewswire.com
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.